Drug intelligence / Profile preview

CabyMar

Development stage: Unknown
Lead developer: EuroEspes Biotecnología
Administration: Oral

Overview

CabyMar (E-CAB-94011) is a marine-derived nutraceutical developed by EuroEspes Biotechnology (Ebiotec). It is obtained from the dorsal muscle of the Atlantic mackerel (*Scomber scombrus*) using non-denaturing biotechnological processes that preserve its bioactive properties. CabyMar is rich in high-biological-value proteins, essential amino acids, polyunsaturated fatty acids (particularly omega-3), vitamins (such as B6, B12, D, and A), and minerals. It exhibits antioxidant, anti-inflammatory, and bioenergizing properties. CabyMar is marketed as a dietary supplement to support immune function, cardiovascular health, and muscle metabolism, and is recommended for conditions such as fatigue, anemia, muscle disorders, and physical deterioration.

Brand names: CabiMarCabyMar
Other names: Atlantic mackerel extractScomber scombrus extract

Beyond the preview

Go deeper on CabyMar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CabyMar.

Explore the full profile